Quality of Life Measurement in Alopecia Areata: Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes

    Pavel V. Chernyshov, Lucía Tomás‐Aragonés, A.Y. Finlay, L. Manolache, S.E. Marrón, Francesca Sampogna, Saskia Spillekom‐van Koulil, Nives Pustišek, Alina Suru, Andrea W.M. Evers, Carmen Sălăvăstru, Åke Svensson, Damiano Abeni, Christine Blome, F. Poot, Gregor B. E. Jemec, Dennis Linder, Matthias Augustin, Anthony Bewley, Sam Salek, Jacek C. Szepietowski
    TLDR Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.
    The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes recommended using the Dermatology Life Quality Index (DLQI), Scalpdex, and AA-specific instruments like the Alopecia Areata Symptom Impact Scale or Alopecia Areata Quality of Life Index to assess health-related quality of life in alopecia areata (AA) patients. Despite limited use and validation of AA-specific instruments, these tools were considered important for evaluating the impact of new treatments on both clinical signs and quality of life. Further validation and development of these instruments were encouraged to better assess outcomes in future treatment trials.
    Discuss this study in the Community →

    Cited in this study

    22 / 22 results

    Related

    1 / 1 results